|
|
Combined treatment modality for anaplastic
oligodendroglioma and oligoastrocytoma: a 10-year update of a phase II study
Jeremic B, Milicic B, Grujicic D, Samardzic M, Antunovic V, Dagovic A,
Aleksandrovic J
Department of Oncology, University Hospital, Kragujevac, Serbia,
Yugoslavia. bjeremic@lrz.tu-muenchen.de
Purpose.
To provide
updated outcome data (10 years) of a Phase II study of combined surgery,
postoperative radiotherapy, and adjuvant chemotherapy in patients with
anaplastic oligodendroglioma and oligoastrocytoma.
Methods and Materials.
In 23 adult patients, surgery, postoperative radiotherapy (60 Gy in 30 daily
fractions within 6 weeks), and adjuvant modified chemotherapy (procarbazine 60
mg/m(2) on Days 1-14, lomustine 100 mg/m(2) on Day 1, and vincristine 1.4
mg/m(2) [maximum 2 mg] on Days 1 and 8) were administered every 6 weeks for up
to six cycles or until progression occurred.
Results.
The median
follow-up was 116 months for all patients.
The median survival time was 118 months, and the 5-year and 10-year survival
rate was 57% and 47%, respectively.
The median time to tumor progression was 78 months, with a 5-year and 10-year
progression-free survival rate of 52% and 39%, respectively.
Gender, age, Karnofsky performance status, location, and histologic type did not
influence survival.
Patients with tumors <or=4 cm did better than those with tumors >4 cm (p =
0.0470), as did those with total tumor resection compared with those with
subtotal tumor resection or biopsy only (p = 0.0024).
Gender, Karnofsky performance status, location, and histologic type did not
influence progression-free survival, but younger age (p = 0.0389), smaller tumor
size (p = 0.0357), and more radical surgery (p = 0.0033) correlated positively
with it.
Acute high-grade (Grade 3 or worse) chemotherapy-related toxicity was mainly
hematologic, with 3 patients (13%) experiencing acute Grade 4 toxicity.
Conclusion.
The results
of this 10-year update confirmed that the trimodality approach is effective in
patients with anaplastic oligodendroglioma and oligoastrocytoma.
PMID: 15145170 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15145170
|
